Charles Retina Institute is offering SUSVIMO, a new, innovative procedure to treat neovascular Age-related Macular Degeneration, or wet AMD.
Wet AMD is the leading cause of blindness in people older than 60. Traditionally, wet AMD is treated with monthly injections into the eye. If the injections are not kept consistent, the disorder can worsen in a matter of months, leading to permanent vision loss. Having to keep track of a schedule of monthly injections, along with arranging rides to and from the clinic and dealing with the side effects, can be a physical and mental burden for patients.
SUSVIMO relieves some of that burden by cutting office visits and treatment down. Instead of monthly injections, patients receive an implant that slowly delivers Ranibizumab into the eye, providing continuous treatment for up to six months. SUSVIMO is just as effective as monthly injections while allowing patients to live without the stress of arranging their lives around monthly trips to their retinal specialist.
This groundbreaking procedure was developed with the assistance of Dr. Stephen Huddleston, MD, a physician at Charles Retina Institute. Dr. Huddleston is the first doctor in the Southeast area to offer SUSVIMO.
For more information of the SUSVIMO procedure, or any of the procedures offered by CRI, click here to be taken to our contact page.